BR112013000607A2 - 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações - Google Patents

5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações

Info

Publication number
BR112013000607A2
BR112013000607A2 BR112013000607A BR112013000607A BR112013000607A2 BR 112013000607 A2 BR112013000607 A2 BR 112013000607A2 BR 112013000607 A BR112013000607 A BR 112013000607A BR 112013000607 A BR112013000607 A BR 112013000607A BR 112013000607 A2 BR112013000607 A2 BR 112013000607A2
Authority
BR
Brazil
Prior art keywords
dihydroquinoline
carboxamide
oxo
chloro
hydroxy
Prior art date
Application number
BR112013000607A
Other languages
English (en)
Inventor
Ulf Tomas Fristedt
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR112013000607A2 publication Critical patent/BR112013000607A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações. a presente invenção proporciona 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2 - di-hidroquinolina-3-carboxamida, seus sais e seus usos.
BR112013000607A 2010-07-09 2011-07-08 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações BR112013000607A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39926410P 2010-07-09 2010-07-09
PCT/US2011/043391 WO2012006544A1 (en) 2010-07-09 2011-07-08 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof

Publications (1)

Publication Number Publication Date
BR112013000607A2 true BR112013000607A2 (pt) 2016-06-28

Family

ID=45439027

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013000607A BR112013000607A2 (pt) 2010-07-09 2011-07-08 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações

Country Status (14)

Country Link
US (3) US20120010239A1 (pt)
EP (2) EP2590653A4 (pt)
JP (2) JP5934202B2 (pt)
KR (1) KR20130041193A (pt)
CN (1) CN102985090B (pt)
AU (2) AU2011274502A1 (pt)
BR (1) BR112013000607A2 (pt)
CA (1) CA2804989A1 (pt)
EA (1) EA201390074A1 (pt)
HK (1) HK1225308A1 (pt)
MX (1) MX2013000332A (pt)
NZ (1) NZ606589A (pt)
WO (1) WO2012006544A1 (pt)
ZA (1) ZA201300957B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2687512A1 (en) * 2005-10-19 2014-01-22 Teva Pharmaceutical Industries Ltd. Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
RS53199B (en) 2007-12-20 2014-06-30 Teva Pharmaceutical Industries Ltd. STABLE LAKVINIMOD PREPARATIONS
PL2442651T3 (pl) * 2009-06-19 2015-12-31 Teva Pharma Leczenie stwardnienia rozsianego za pomocą lakwinimodu
KR20160148050A (ko) * 2009-07-30 2016-12-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 크론병의 치료
ES2586843T3 (es) 2009-08-10 2016-10-19 Teva Pharmaceutical Industries Ltd. Tratamiento de trastornos relacionados con BDNF usando laquinimod
MX337614B (es) 2010-03-03 2016-03-10 Teva Pharma Tratamiento de lupus nefritis usando laquinimod.
CN105796556A (zh) * 2010-03-03 2016-07-27 泰华制药工业有限公司 用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎
EA025377B1 (ru) 2010-07-09 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
MX2014004420A (es) 2011-10-12 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod.
TW201345527A (zh) 2012-02-03 2013-11-16 Teva Pharma 拉喹莫德於治療對第一線抗－ＴＮＦα療法無效之克隆氏症患者之用途
SG11201404419WA (en) 2012-02-16 2014-10-30 Teva Pharma N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
MX2015010967A (es) 2013-03-14 2015-10-26 Teva Pharma Formulaciones transdermicas de laquinimod.
JP2016514162A (ja) * 2013-03-14 2016-05-19 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶およびその製造のための改善された方法
CA2945978A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
US20190090046A1 (en) * 2017-09-21 2019-03-21 Bragi GmbH Tactile Feedback for Audio Defined Menu System and Method

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2380420A (en) * 1940-12-16 1945-07-31 William S Emerson Production of secondary and tertiary amines from nitrogen compounds
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3724018A1 (de) * 1987-07-21 1989-02-02 Bayer Ag Verfahren zur trennung von anilin-derivaten
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
EP2687512A1 (en) 2005-10-19 2014-01-22 Teva Pharmaceutical Industries Ltd. Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
RS53199B (en) * 2007-12-20 2014-06-30 Teva Pharmaceutical Industries Ltd. STABLE LAKVINIMOD PREPARATIONS
EP2318371A2 (en) * 2008-07-01 2011-05-11 Actavis Group PTC EHF Novel solid state forms of laquinimod and its sodium salt
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
MX2013000332A (es) 2013-02-26
JP2016053049A (ja) 2016-04-14
EP3056205A1 (en) 2016-08-17
AU2017261621A1 (en) 2017-12-07
EA201390074A1 (ru) 2013-06-28
AU2011274502A1 (en) 2013-02-28
US20160279121A1 (en) 2016-09-29
JP5934202B2 (ja) 2016-06-15
WO2012006544A1 (en) 2012-01-12
KR20130041193A (ko) 2013-04-24
US20180140592A1 (en) 2018-05-24
CN102985090A (zh) 2013-03-20
US20120010239A1 (en) 2012-01-12
NZ606589A (en) 2015-03-27
ZA201300957B (en) 2014-04-30
JP2013534536A (ja) 2013-09-05
EP2590653A1 (en) 2013-05-15
HK1225308A1 (zh) 2017-09-08
CA2804989A1 (en) 2012-01-12
EP2590653A4 (en) 2014-01-01
CN102985090B (zh) 2014-11-26

Similar Documents

Publication Publication Date Title
BR112013000607A2 (pt) 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações
BR112013000599A2 (pt) deuterado n-etil-n-fenil-1,2-di-hidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolino-3-carboxamida, os seus sais e suas utilizações
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
JP2014501485A5 (pt)
BR112013016737A2 (pt) artigo absorvente.
UY34582A (es) Anticuerpos anti-cxcr3
UY4210Q (es) Silla
BR112014027814A2 (pt) agentes sinérgicos antimicrobianos.
BR112013030540A2 (pt) tecido elástico.
BR112014028443A2 (pt) composição estéril.
UY4248Q (es) Silla
BR112015002986A2 (pt) adjuvante de adesividade, adjuvante de espalhamento-adesividade, e, composição agroquímica
CL2011002741S1 (es) Reposera.
UY33207A (es) Métodos de preparación de tiazolidinas
TR201111860U (tr) Rozetli bariyer.
CL2012002144S1 (es) Silla
CL2012002142S1 (es) Silla
CL2012002143S1 (es) Silla
CL2012002141S1 (es) Silla
TN2011000399A1 (fr) دراجة كهربائية ذات شحن الي
ITRN20130039U1 (it) Erpice frangizolla a dischi indipendenti.
CL2012003679S1 (es) Licuadora
ES1108230Y (es) Sobre plano.
UY4267Q (es) Botella
UY4262Q (es) Botella

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.